Andrea Gallina

List of Publications by Citations

263 papers	8,539 citations	51 h-index	82 g-index
431 ext. papers	10,085 ext. citations	3.6 avg, IF	5.33 L-index

#	Paper	IF	Citations
263	Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. *European Urology*, **2012**, 61, 480-7	10.2	425
262	Complications and other surgical outcomes associated with extended pelvic lymphadenectomy in men with localized prostate cancer. *European Urology*, **2006**, 50, 1006-13	10.2	266
261	Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study. *Journal of Clinical Oncology*, **2018**, 36, 3353-3360	2.2	265
260	Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy. *European Urology*, **2009**, 55, 261-70	10.2	213
259	A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer. *Journal of Clinical Oncology*, **2007**, 25, 3576-81	2.2	164
258	Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography. *European Urology*, **2011**, 60, 935-43	10.2	163
257	Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years. *European Urology*, **2015**, 67, 299-309	10.2	158
256	C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality: a European study of 313 patients. *Cancer*, **2007**, 110, 1241-7	6.4	155
255	Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: results of a matched analysis. *European Urology*, **2011**, 59, 832-40	10.2	141
254	Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy. *European Urology*, **2009**, 55, 1003-11	10.2	138
253	Validation of a nomogram predicting the probability of lymph node invasion based on the extent of pelvic lymphadenectomy in patients with clinically localized prostate cancer. *BJU International*, **2006**, 98, 788-93	5.6	137
252	Critical assessment of ideal nodal yield at pelvic lymphadenectomy to accurately diagnose prostate cancer nodal metastasis in patients undergoing radical retropubic prostatectomy. *Urology*, **2007**, 69, 147-51	1.6	131
251	Impact on sexual function of holmium laser enucleation versus transurethral resection of the prostate: results of a prospective, 2-center, randomized trial. *Journal of Urology*, **2006**, 175, 1817-21	2.5	129
250	Prognostic value of lymph node dissection in patients with muscle-invasive transitional cell carcinoma of the upper urinary tract. *European Urology*, **2008**, 53, 794-802	10.2	124
249	Comparison of stage migration patterns between Europe and the USA: an analysis of 11 350 men treated with radical prostatectomy for prostate cancer. *BJU International*, **2008**, 101, 1513-8	5.6	122
248	Extended 21-sample needle biopsy protocol for diagnosis of prostate cancer in 1000 consecutive patients. *European Urology*, **2007**, 52, 430-5	10.2	120
247	Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies. *European Urology*, **2020**, 77, 439-446	10.2	119

246	Improving the preservation of the urethral sphincter and neurovascular bundles during open radical retropubic prostatectomy. *European Urology*, **2005**, 48, 938-45	10.2	118
245	When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool. *European Urology*, **2010**, 57, 551-8	10.2	112
244	Clinicians are poor raters of life-expectancy before radical prostatectomy or definitive radiotherapy for localized prostate cancer. *BJU International*, **2007**, 100, 1254-8	5.6	107
243	Performance characteristics of computed tomography in detecting lymph node metastases in contemporary patients with prostate cancer treated with extended pelvic lymph node dissection. *European Urology*, **2012**, 61, 1132-8	10.2	95
242	Are infertile men less healthy than fertile men? Results of a prospective case-control survey. *European Urology*, **2009**, 56, 1025-31	10.2	94
241	Biopsy core number represents one of foremost predictors of clinically significant gleason sum upgrading in patients with low-risk prostate cancer. *Urology*, **2009**, 73, 1087-91	1.6	93
240	Development and external validation of an extended 10-core biopsy nomogram. *European Urology*, **2007**, 52, 436-44	10.2	91
239	Selecting the optimal candidate for adjuvant radiotherapy after radical prostatectomy for prostate cancer: a long-term survival analysis. *European Urology*, **2013**, 63, 998-1008	10.2	88
238	Predicting erectile function recovery after bilateral nerve sparing radical prostatectomy: a proposal of a novel preoperative risk stratification. *Journal of Sexual Medicine*, **2010**, 7, 2521-31	1.1	85
237	Holmium laser enucleation versus open prostatectomy for benign prostatic hyperplasia: an inpatient cost analysis. *Urology*, **2006**, 68, 302-6	1.6	85
236	Biopsy schemes with the fewest cores for detecting 95% of the prostate cancers detected by a 24-core biopsy. *European Urology*, **2010**, 57, 1-8	10.2	83
235	Benign Prostatic Hyperplasia and Its Aetiologies. *European Urology Supplements*, **2009**, 8, 865-871	0.9	75
234	Nerve-sparing approach during radical prostatectomy is strongly associated with the rate of postoperative urinary continence recovery. *BJU International*, **2013**, 111, 717-22	5.6	73
233	Trans-rectal versus trans-perineal saturation rebiopsy of the prostate: is there a difference in cancer detection rate?. *Urology*, **2011**, 77, 921-5	1.6	73
232	CURRENTLY USED CRITERIA FOR ACTIVE SURVEILLANCE IN MEN WITH LOW RISK PROSTATE CANCER. AN ANALYSIS OF PATHOLOGICAL FEATURES. *Journal of Urology*, **2008**, 179, 152-152	2.5	71
231	Acceptance of and discontinuation rate from erectile dysfunction oral treatment in patients following bilateral nerve-sparing radical prostatectomy. *European Urology*, **2008**, 53, 564-70	10.2	70
230	Tumour volume and high grade tumour volume are the best predictors of pathologic stage and biochemical recurrence after radical prostatectomy. *European Journal of Cancer*, **2007**, 43, 536-43	7.5	69
229	Impact of adjuvant radiation therapy on urinary continence recovery after radical prostatectomy. *European Urology*, **2014**, 65, 546-51	10.2	68

228	Percentage of positive biopsy cores can improve the ability to predict lymph node invasion in patients undergoing radical prostatectomy and extended pelvic lymph node dissection. *European Urology*, **2007**, 51, 1573-81	10.2	68
227	Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer. *European Urology*, **2020**, 77, 701-710	10.2	66
226	Initial biopsy outcome prediction--head-to-head comparison of a logistic regression-based nomogram versus artificial neural network. *European Urology*, **2007**, 51, 1236-40; discussion 1241-3	10.2	66
225	Prostate volume and adverse prostate cancer features: fact not artifact. *European Journal of Cancer* , **2007**, 43, 2669-77	7.5	66
224	Extended pelvic lymph node dissection in prostate cancer: a 20-year audit in a single center. *Annals of Oncology*, **2013**, 24, 1459-66	10.3	65
223	Prostate cancer nomograms: an update. *European Urology*, **2006**, 50, 914-26; discussion 926	10.2	65
222	Apparent diffusion coefficient value and ratio as noninvasive potential biomarkers to predict prostate cancer grading: comparison with prostate biopsy and radical prostatectomy specimen. *American Journal of Roentgenology*, **2015**, 204, 550-7	5.4	64
221	Baseline potency in candidates for bilateral nerve-sparing radical retropubic prostatectomy. *European Urology*, **2006**, 50, 360-5	10.2	63
220	Long-term biochemical recurrence rates after robot-assisted radical prostatectomy: analysis of a single-center series of patients with a minimum follow-up of 5 years. *Urology*, **2012**, 79, 133-8	1.6	60
219	Lymphatic spread of nodal metastases in high-risk prostate cancer: The ascending pathway from the pelvis to the retroperitoneum. *Prostate*, **2012**, 72, 186-92	4.2	58
218	Preserved postoperative penile size correlates well with maintained erectile function after bilateral nerve-sparing radical retropubic prostatectomy. *European Urology*, **2007**, 52, 702-7	10.2	56
217	Surgical volume is related to the rate of positive surgical margins at radical prostatectomy in European patients. *BJU International*, **2006**, 98, 1204-9	5.6	56
216	Prediction of functional outcomes after nerve-sparing radical prostatectomy: results of conditional survival analyses. *European Urology*, **2012**, 62, 42-52	10.2	54
215	A nomogram for staging of exclusive nonobturator lymph node metastases in men with localized prostate cancer. *European Urology*, **2007**, 51, 112-9; discussion 119-20	10.2	54
214	Serum sex steroids depict a nonlinear u-shaped association with high-risk prostate cancer at radical prostatectomy. *Clinical Cancer Research*, **2012**, 18, 3648-57	12.9	53
213	Impact of surgical volume on the rate of lymph node metastases in patients undergoing radical prostatectomy and extended pelvic lymph node dissection for clinically localized prostate cancer. *European Urology*, **2008**, 54, 794-802	10.2	52
212	Extent of lymph node dissection at nephrectomy affects cancer-specific survival and metastatic progression in specific sub-categories of patients with renal cell carcinoma (RCC). *BJU International*, **2014**, 114, 210-5	5.6	51
211	Menstrual cycle-related changes in circulating androgens in healthy women with self-reported normal sexual function. *Journal of Sexual Medicine*, **2008**, 5, 854-863	1.1	50

210	Development and split-sample validation of a nomogram predicting the probability of seminal vesicle invasion at radical prostatectomy. *European Urology*, **2007**, 52, 98-105	10.2	48
209	Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. *European Urology*, **2020**, 77, 636-643	10.2	48
208	The human cytomegalovirus UL45 gene product is a late, virion-associated protein and influences virus growth at low multiplicities of infection. *Journal of General Virology*, **2003**, 84, 3359-3370	4.9	46
207	Incidence and effect of variant histology on oncological outcomes in patients with bladder cancer treated with radical cystectomy. *Urologic Oncology: Seminars and Original Investigations*, **2017**, 35, 335-341	2.8	45
206	Preoperative hypogonadism is not an independent predictor of high-risk disease in patients undergoing radical prostatectomy. *Cancer*, **2011**, 117, 3953-62	6.4	44
205	PATIENTS WITH ORGAN CONFINED PROSTATE CANCER AND POSTITIVE SURGICAL MARGINS HAVE SIMILAR RECURRENCE RATES COMPARED TO PATIENTS WITH EXTRA-CAPSULAR EXTENSION AND NEGATIVE SURGICAL MARGINS. A PLEA FOR STAGE RE-CLASSIFICATION. *Journal of Urology*, **2009**, 181, 290-296	2.5	44
204	Predicting the risk of bone metastasis in prostate cancer. *Cancer Treatment Reviews*, **2014**, 40, 3-11	14.4	43
203	Topical prilocaine-lidocaine cream combined with peripheral nerve block improves pain control in prostatic biopsy: results from a prospective randomized trial. *European Urology*, **2008**, 53, 967-73	10.2	43
202	Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence. *European Urology*, **2008**, 54, 118-25	10.2	43
201	How can we predict lymphorrhoea and clinically significant lymphocoeles after radical prostatectomy and pelvic lymphadenectomy? Clinical implications. *BJU International*, **2011**, 107, 1095-101	5.6	42
200	Obesity does not predispose to more aggressive prostate cancer either at biopsy or radical prostatectomy in European men. *International Journal of Cancer*, **2007**, 121, 791-5	7.5	42
199	Testing the most stringent criteria for selection of candidates for active surveillance in patients with low-risk prostate cancer. *BJU International*, **2010**, 105, 1548-52	5.6	41
198	Drug Insight: oral phosphodiesterase type 5 inhibitors for erectile dysfunction. *Nature Reviews Urology*, **2005**, 2, 239-47		40
197	The Impact of Experience on the Risk of Surgical Margins and Biochemical Recurrence after Robot-Assisted Radical Prostatectomy: A Learning Curve Study. *Journal of Urology*, **2019**, 202, 108-113	2.5	40
196	Metabolic syndrome and benign prostatic hyperplasia: evidence of a potential relationship, hypothesized etiology, and prevention. *Korean Journal of Urology*, **2011**, 52, 507-16		38
195	Surgical Safety of Radical Cystectomy and Pelvic Lymph Node Dissection Following Neoadjuvant Pembrolizumab in Patients with Bladder Cancer: Prospective Assessment of Perioperative Outcomes from the PURE-01 Trial. *European Urology*, **2020**, 77, 576-580	10.2	38
194	Holmium laser enucleation of the prostate and holmium laser ablation of the prostate: indications and outcome. *Current Opinion in Urology*, **2009**, 19, 38-43	2.8	37
193	Use of preoperative plasma endoglin for prediction of lymph node metastasis in patients with clinically localized prostate cancer. *Clinical Cancer Research*, **2008**, 14, 1418-22	12.9	37

192	When to perform lymph node dissection in patients with renal cell carcinoma: a novel approach to the preoperative assessment of risk of lymph node invasion at surgery and of lymph node progression during follow-up. *BJU International*, **2013**, 112, E59-66	5.6	35
191	THE EFFECT OF ANDROGEN DEPRIVATION THERAPY ON THE RATE OF SUBSEQUENT NON-CANCER MORBIDITIES. *Journal of Urology*, **2008**, 179, 186-186	2.5	35
190	Robot-assisted Salvage Lymph Node Dissection for Clinically Recurrent Prostate Cancer. *European Urology*, **2017**, 72, 432-438	10.2	32
189	What is the definition of a satisfactory erectile function after bilateral nerve sparing radical prostatectomy?. *Journal of Sexual Medicine*, **2011**, 8, 1210-7	1.1	32
188	Acceptance of and discontinuation rate from paroxetine treatment in patients with lifelong premature ejaculation. *Journal of Sexual Medicine*, **2009**, 6, 2868-77	1.1	32
187	Remembered International Index of Erectile Function domain scores are not accurate in assessing preoperative potency in candidates for bilateral nerve-sparing radical retropubic prostatectomy. *Journal of Sexual Medicine*, **2008**, 5, 677-83	1.1	32
186	Differences in the rate of lymph node invasion in men with clinically localized prostate cancer might be related to the continent of origin. *BJU International*, **2007**, 100, 528-32	5.6	32
185	Mortality at 120 days after prostatic biopsy: a population-based study of 22,175 men. *International Journal of Cancer*, **2008**, 123, 647-52	7.5	32
184	Does diabetes mellitus increase the risk of high-grade prostate cancer in patients undergoing radical prostatectomy?. *Prostate Cancer and Prostatic Diseases*, **2011**, 14, 74-8	6.2	31
183	Circulating estradiol, but not testosterone, is a significant predictor of high-grade prostate cancer in patients undergoing radical prostatectomy. *Cancer*, **2011**, 117, 5029-38	6.4	31
182	Preoperative erectile function represents a significant predictor of postoperative urinary continence recovery in patients treated with bilateral nerve sparing radical prostatectomy. *Journal of Urology*, **2012**, 187, 569-74	2.5	30
181	Nerve-sparing radical retropubic prostatectomy in patients previously submitted to holmium laser enucleation of the prostate for bladder outlet obstruction due to benign prostatic enlargement. *European Urology*, **2008**, 53, 1180-5	10.2	30
180	Choosing the best candidates for penile rehabilitation after bilateral nerve-sparing radical prostatectomy. *Journal of Sexual Medicine*, **2012**, 9, 608-17	1.1	29
179	Erectile function outcome after bilateral nerve sparing radical prostatectomy: which patients may be left untreated?. *Journal of Sexual Medicine*, **2012**, 9, 903-8	1.1	29
178	External validation of the European association of urology recommendations for pelvic lymph node dissection in patients treated with robot-assisted radical prostatectomy. *Journal of Endourology*, **2014**, 28, 416-23	2.7	29
177	The role of transrectal saturation biopsy in tumour localization: pathological correlation after retropubic radical prostatectomy and implication for focal ablative therapy. *BJU International*, **2011** , 108, 366-71	5.6	29
176	Systematic assessment of the ability of the number and percentage of positive biopsy cores to predict pathologic stage and biochemical recurrence after radical prostatectomy. *European Urology* , **2007**, 52, 733-43	10.2	29
175	Management of erectile dysfunction after radical prostatectomy in 2007. *World Journal of Urology*, **2007**, 25, 143-8	4	29

174	A Detailed Analysis of the Association Between Postoperative Phosphodiesterase Type 5 Inhibitor Use and the Risk of Biochemical Recurrence After Radical Prostatectomy. *European Urology*, **2015**, 68, 750-3	10.2	28
173	Impact of the introduction of a robotic training programme on prostate cancer stage migration at a single tertiary referral centre. *BJU International*, **2013**, 111, 1222-30	5.6	28
172	Unilateral positive biopsies in low risk prostate cancer patients diagnosed with extended transrectal ultrasound-guided biopsy schemes do not predict unilateral prostate cancer at radical prostatectomy. *BJU International*, **2012**, 110, E64-8	5.6	27
171	The optimal rebiopsy prostatic scheme depends on patient clinical characteristics: results of a recursive partitioning analysis based on a 24-core systematic scheme. *European Urology*, **2011**, 60, 834-41	10.2	27
170	Accuracy of life tables in predicting overall survival in candidates for radiotherapy for prostate cancer. *International Journal of Radiation Oncology Biology Physics*, **2007**, 69, 88-94	4	26
169	Differences in trends in the use of robot-assisted and open radical cystectomy and changes over time in peri-operative outcomes among selected centres in North America and Europe: an international multicentre collaboration. *BJU International*, **2019**, 124, 656	5.6	25
168	Preoperative sex steroids are significant predictors of early biochemical recurrence after radical prostatectomy. *World Journal of Urology*, **2013**, 31, 275-80	4	25
167	Prostate cancer-specific survival in men treated with hormonal therapy after failure of radical prostatectomy. *European Urology*, **2007**, 52, 446-52	10.2	25
166	Penile implants in the era of oral drug treatment for erectile dysfunction. *BJU International*, **2004**, 94, 745-51	5.6	25
165	Random biopsy: when, how many and where to take the cores?. *World Journal of Urology*, **2014**, 32, 859-69	4	24
164	Fifteen-year single-centre experience with three different surgical procedures of nerve-sparing cystectomy in selected organ-confined bladder cancer patients. *World Journal of Urology*, **2015**, 33, 1389-95	4	24
163	Predictive models before and after radical prostatectomy. *Prostate*, **2010**, 70, 1371-8	4.2	24
162	Body mass index does not predict prostate-specific antigen or percent free prostate-specific antigen in men undergoing prostate cancer screening. *European Journal of Cancer*, **2007**, 43, 1180-7	7.5	24
161	Influence of obesity on tumour volume in patients with prostate cancer. *BJU International*, **2012**, 109, 678-84	5.6	22
160	Age-adjusted validation of the most stringent criteria for active surveillance in low-risk prostate cancer patients. *Cancer*, **2012**, 118, 973-80	6.4	22
159	A nomogram is more accurate than a regression tree in predicting lymph node invasion in prostate cancer. *BJU International*, **2008**, 101, 556-60	5.6	21
158	Preoperative plasma HER2 and epidermal growth factor receptor for staging and prognostication in patients with clinically localized prostate cancer. *Clinical Cancer Research*, **2007**, 13, 5377-84	12.9	21
157	Evaluation of positive surgical margins in patients undergoing robot-assisted and open radical prostatectomy according to preoperative risk groups. *Urologic Oncology: Seminars and Original Investigations*, **2016**, 34, 57.e1-7	2.8	20

156	Pure but Not Mixed Histologic Variants Are Associated With Poor Survival at Radical Cystectomy in Bladder Cancer Patients. *Clinical Genitourinary Cancer*, **2017**, 15, e603-e607	3.3	20
155	Head-to-head comparison of lymph node density and number of positive lymph nodes in stratifying the outcome of patients with lymph node-positive prostate cancer submitted to radical prostatectomy and extended lymph node dissection. *Urologic Oncology: Seminars and Original Investigations*, **2014**, 32, 29.e21-8	2.8	20
154	Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer. *BJU International*, **2013**, 111, 723-30	5.6	20
153	Indications for pelvic nodal treatment in prostate cancer should change. Validation of the Roach formula in a large extended nodal dissection series. *International Journal of Radiation Oncology Biology Physics*, **2012**, 83, 624-9	4	20
152	Prostate saturation biopsy following a first negative biopsy: state of the art. *Urologia Internationalis* , **2012**, 89, 126-35	1.9	20
151	Apparent diffusion coefficient in the evaluation of side-specific extracapsular extension in prostate cancer: Development and external validation of a nomogram of clinical use. *Urologic Oncology: Seminars and Original Investigations*, **2016**, 34, 291.e9-291.e17	2.8	19
150	How to optimize patient selection for robot-assisted radical prostatectomy: functional outcome analyses from a tertiary referral center. *Journal of Endourology*, **2014**, 28, 792-800	2.7	19
149	National Comprehensive Cancer Network practice guidelines 2011: Need for more accurate recommendations for pelvic lymph node dissection in prostate cancer. *Journal of Urology*, **2012**, 188, 423-8	2.5	19
148	External validation of a nomogram for prediction of side-specific extracapsular extension at robotic radical prostatectomy. *Journal of Endourology*, **2007**, 21, 1345-51	2.7	19
147	Critical assessment of the European Association of Urology guideline indications for pelvic lymph node dissection at radical prostatectomy. *BJU International*, **2011**, 108, 1769-75	5.6	18
146	Balancing continence function and oncological outcomes during robot-assisted radical prostatectomy (RARP). *BJU International*, **2011**, 108, 999-1006	5.6	18
145	Extended pelvic lymph node dissection does not affect erectile function recovery in patients treated with bilateral nerve-sparing radical prostatectomy. *Journal of Sexual Medicine*, **2012**, 9, 2187-94	1.1	17
144	Postoperative phosphodiesterase type 5 inhibitor administration increases the rate of urinary continence recovery after bilateral nerve-sparing radical prostatectomy. *International Journal of Urology*, **2013**, 20, 413-9	2.3	17
143	When should we expect no residual tumor (pT0) once we submit incidental T1a-b prostate cancers to radical prostatectomy?. *International Journal of Urology*, **2011**, 18, 148-53	2.3	17
142	Prostate-specific antigen improves the ability of clinical stage and biopsy Gleason sum to predict the pathologic stage at radical prostatectomy in the new millennium. *European Urology*, **2007**, 52, 1067-74	10.2	17
141	Sperm banking is of key importance in patients with prostate cancer. *Fertility and Sterility*, **2013**, 100, 367-72.e1	4.8	16
140	Distribution of prostate specific antigen (PSA) and percentage free PSA in a contemporary screening cohort with no evidence of prostate cancer. *BJU International*, **2007**, 100, 37-41	5.6	16
139	Zonal origin of localized prostate cancer does not affect the rate of biochemical recurrence after radical prostatectomy. *European Urology*, **2007**, 51, 949-55; discussion 955	10.2	16

138	Prediction of pathological stage is inaccurate in men with PSA values above 20 ng/mL. *European Urology*, **2007**, 52, 1374-80	10.2	16
137	Timing of blood transfusion and not ABO blood type is associated with survival in patients treated with radical cystectomy for nonmetastatic bladder cancer: Results from a single high-volume institution. *Urologic Oncology: Seminars and Original Investigations*, **2016**, 34, 256.e7-256.e13	2.8	15
136	Assessing the most accurate formula to predict the risk of lymph node metastases from prostate cancer in contemporary patients treated with radical prostatectomy and extended pelvic lymph node dissection. *Radiotherapy and Oncology*, **2013**, 109, 211-6	5.3	15
135	The probability of Gleason score upgrading between biopsy and radical prostatectomy can be accurately predicted. *International Journal of Urology*, **2009**, 16, 526-9	2.3	15
134	Sex hormone-binding globulin: a novel marker for nodal metastases prediction in prostate cancer patients undergoing extended pelvic lymph node dissection. *Urology*, **2009**, 73, 850-5	1.6	15
133	Does educational status affect a patient's behavior toward erectile dysfunction?. *Journal of Sexual Medicine*, **2008**, 5, 1941-8	1.1	15
132	Health-insurance status is a determinant of the stage at presentation and of cancer control in European men treated with radical prostatectomy for clinically localized prostate cancer. *BJU International*, **2007**, 99, 1404-8	5.6	15
131	Predicting the Pathologic Complete Response After Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer. *Journal of the National Cancer Institute*, **2021**, 113, 48-53	9.7	15
130	Effect on postoperative survival of the status of distal ureteral margin: The necessity to achieve negative margins at the time of radical cystectomy. *Urologic Oncology: Seminars and Original Investigations*, **2016**, 34, 59.e15-22	2.8	14
129	Is sperm banking of interest to patients with nongerm cell urological cancer before potentially fertility damaging treatments?. *Journal of Urology*, **2009**, 182, 1101-7	2.5	14
128	GENDER IS AN IMPORTANT PREDICTOR OF CANCER-SPECIFIC SURVIVAL IN PATIENT WITH TRANSITIONAL CELL CARCINOMA AFTER RADICAL CYSTECTOMY. *Journal of Urology*, **2009**, 181, 635	2.5	14
127	Role of urinary cathepsin B and L in the detection of bladder urothelial cell carcinoma. *Journal of Urology*, **2008**, 179, 478-84; discussion 484	2.5	14
126	Bone metastases are infrequent in patients with newly diagnosed prostate cancer: analysis of their clinical and pathologic features. *Urology*, **2006**, 68, 362-6	1.6	14
125	The presence of carcinoma in situ at radical cystectomy increases the risk of urothelial recurrence: Implications for follow-up schemes. *Urologic Oncology: Seminars and Original Investigations*, **2017**, 35, 151.e17-151.e23	2.8	13
124	F-FDG PET/CT and Urothelial Carcinoma: Impact on Management and Prognosis-A Multicenter Retrospective Study. *Cancers*, **2019**, 11,	6.6	13
123	Are Caucasian-European men delaying fatherhood? Results of a 7 year observational study of infertile couples with male factor infertility. *Journal of Developmental and Physical Disabilities*, **2012**, 35, 125-32		13
122	Does the transrectal ultrasound probe influence prostate cancer detection in patients undergoing an extended prostate biopsy scheme? Results of a large retrospective study. *BJU International*, **2012**, 109, 672-7	5.6	13
121	A novel tool to assess the risk of urinary incontinence after nerve-sparing radical prostatectomy. *BJU International*, **2013**, 111, 905-13	5.6	13

120	Postoperative orgasmic function increases over time in patients undergoing nerve-sparing radical prostatectomy. *Journal of Sexual Medicine*, **2010**, 7, 149-55	1.1	13
119	Effect of autologous blood transfusion on the rate of biochemical recurrence after radical prostatectomy. *BJU International*, **2007**, 100, 1249-53	5.6	13
118	Pfannenstiel versus vertical laparotomy in patients undergoing radical retropubic prostatectomy with spinal anesthesia: results of a prospective, randomized trial. *European Urology*, **2005**, 47, 202-8	10.2	13
117	Sex-specific Alterations in the Urinary and Tissue Microbiome in Therapy-naïve Urothelial Bladder Cancer Patients. *European Urology Oncology*, **2020**, 3, 784-788	6.7	12
116	Surgical treatment for clinical node-positive bladder cancer patients treated with radical cystectomy without neoadjuvant chemotherapy. *World Journal of Urology*, **2018**, 36, 639-644	4	12
115	Comparison between the diagnostic accuracies of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and conventional imaging in recurrent urothelial carcinomas: a retrospective, multicenter study. *Abdominal Radiology*, **2018**, 43, 2391-2399	3	12
114	Optimizing postoperative sexual function after radical prostatectomy. *Therapeutic Advances in Urology*, **2012**, 4, 347-65	3.2	12
113	Non-surgically related causes of erectile dysfunction after bilateral nerve-sparing radical prostatectomy. *Prostate Cancer and Prostatic Diseases*, **2016**, 19, 185-90	6.2	12
112	Location of Metastatic Bladder Cancer as a Determinant of In-hospital Mortality After Radical Cystectomy. *European Urology Oncology*, **2018**, 1, 169-175	6.7	12
111	Unfavorable Cancer-specific Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients With Bladder Cancer and Squamous Cell Variant: A Multi-institutional Study. *Clinical Genitourinary Cancer*, **2020**, 18, e543-e556	3.3	11
110	The number of cores taken in patients diagnosed with a single microfocus at initial biopsy is a major predictor of insignificant prostate cancer. *Journal of Urology*, **2013**, 189, 854-9	2.5	11
109	Presence of positive surgical margin in patients with organ-confined prostate cancer equals to extracapsular extension negative surgical margin. A plea for TNM staging system reclassification. *Urologic Oncology: Seminars and Original Investigations*, **2013**, 31, 1497-503	2.8	11
108	There is no way to identify patients who will harbor small volume, unilateral prostate cancer at final pathology. implications for focal therapies. *Prostate*, **2012**, 72, 925-30	4.2	11
107	Sex hormone-binding globulin is a significant predictor of extracapsular extension in men undergoing radical prostatectomy. *BJU International*, **2011**, 107, 1243-9	5.6	11
106	More Extensive Lymph Node Dissection Improves Survival Benefit of Radical Cystectomy in Metastatic Urothelial Carcinoma of the Bladder. *Clinical Genitourinary Cancer*, **2019**, 17, 105-113.e2	3.3	11
105	Is transurethral resection alone enough for the diagnosis of histological variants? A single-center study. *Urologic Oncology: Seminars and Original Investigations*, **2017**, 35, 528.e1-528.e5	2.8	10
104	Myriocin treatment of CF lung infection and inflammation: complex analyses for enigmatic lipids. *Naunyn-Schmiedeberg's Archives of Pharmacology*, **2017**, 390, 775-790	3.4	10
103	Pattern of node metastases in patients treated with radical cystectomy and extended or superextended pelvic lymph node dissection due to bladder cancer. *Urologic Oncology: Seminars and Original Investigations*, **2018**, 36, 307.e9-307.e14	2.8	10

102	Preoperative Favorable Characteristics in Bladder Cancer Patients Cannot Substitute the Necessity of Extended Lymphadenectomy During Radical Cystectomy: A Sensitivity Curve Analysis. *Urology*, **2016**, 88, 97-103	1.6	10
101	Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect. *European Urology*, **2019**, 76, 425-429	10.2	10
100	Assessing the risk of lymph node invasion in patients with intermediate risk prostate cancer treated with extended pelvic lymph node dissection. A novel prediction tool. *Prostate*, **2012**, 72, 499-506	4.2	10
99	Unmarried men have worse oncologic outcomes after radical cystectomy for nonmetastatic urothelial bladder cancer. *Urologic Oncology: Seminars and Original Investigations*, **2020**, 38, 76.e1-76.e9	2.8	10
98	The effect of age and comorbidities on early postoperative complications after radical cystectomy: A contemporary population-based analysis. *Journal of Geriatric Oncology*, **2019**, 10, 623-631	3.6	9
97	Can Patients with Muscle-invasive Bladder Cancer and Fibroblast Growth Factor Receptor-3 Alterations Still Be Considered for Neoadjuvant Pembrolizumab? A Comprehensive Assessment from the Updated Results of the PURE-01 Study. *European Urology Oncology*, **2020**, 4, 1001-1001	6.7	9
96	Incidence and Predictors of 30-Day Readmission in Patients Treated With Radical Cystectomy: A Single Center European Experience. *Clinical Genitourinary Cancer*, **2016**, 14, e341-6	3.3	9
95	Ejaculatory disorders may affect screening for prostate cancer. *Journal of Urology*, **2007**, 178, 232-7; discussion 237-8	2.5	9
94	Sunitinib relieves renal cell carcinoma spinal cord compression. *European Urology*, **2007**, 51, 1741-3	10.2	9
93	Neoadjuvant Chemotherapy or Immunotherapy for Clinical T2N0 Muscle-invasive Bladder Cancer: Time to Change the Paradigm?. *European Urology Oncology*, **2020**,	6.7	9
92	Is neoadjuvant chemotherapy for pT2 bladder cancer associated with a survival benefit in a population-based analysis?. *Cancer Epidemiology*, **2019**, 58, 83-88	2.8	9
91	Contemporary Trends and Survival Outcomes After Aborted Radical Prostatectomy in Lymph Node Metastatic Prostate Cancer Patients. *European Urology Focus*, **2019**, 5, 381-388	5.1	9
90	Impact of Intra- and Postoperative Blood Transfusion on the Incidence, Timing, and Pattern of Disease Recurrence After Radical Cystectomy. *Clinical Genitourinary Cancer*, **2017**, 15, e681-e688	3.3	8
89	Impact of Prostate Involvement on Outcomes in Patients Treated with Radical Cystoprostatectomy for Bladder Cancer. *Urologia Internationalis*, **2017**, 98, 290-297	1.9	8
88	The Value of Multiparametric Magnetic Resonance Imaging Sequences to Assist in the Decision Making of Muscle-invasive Bladder Cancer. *European Urology Oncology*, **2021**, 4, 829-833	6.7	8
87	Neoadjuvant and adjuvant treatment in high-risk prostate cancer. *Expert Review of Clinical Pharmacology*, **2018**, 11, 425-438	3.8	8
86	Preoperative erectile function is the only predictor of the use of a high number of phosphodiesterase type-5 inhibitors after bilateral nerve-sparing radical prostatectomy. *International Journal of Impotence Research*, **2014**, 26, 201-4	2.3	8
85	Anatomical radical retropubic prostatectomy in patients with a preexisting three-piece inflatable prosthesis: a series of case reports. *Journal of Sexual Medicine*, **2009**, 6, 578-83	1.1	8

84	Obesity does not increase the risk of lymph node metastases in patients with clinically localized prostate cancer undergoing radical prostatectomy and extended pelvic lymph node dissection. *International Journal of Urology*, **2009**, 16, 676-81	2.3	8
83	Reliability of classification of erectile function domain of the international index of erectile function in patients affected by localized prostate cancer who are candidates for radical prostatectomy. *Urology*, **2005**, 66, 1140; author reply 1140-1	1.6	8
82	Development of a New Comorbidity Assessment Tool for Specific Prediction of Perioperative Mortality in Contemporary Patients Treated with Radical Cystectomy. *Annals of Surgical Oncology*, **2019**, 26, 1942-1949	3.1	7
81	Open Versus Robotic Cystectomy: A Propensity Score Matched Analysis Comparing Survival Outcomes. *Journal of Clinical Medicine*, **2019**, 8,	5.1	7
80	Lower urinary tract symptoms affect one-third of men in a prostate cancer screening population. *Journal of Endourology*, **2008**, 22, 369-76	2.7	7
79	MP70-15 LONG TERM OUTCOMES OF SALVAGE LYMPH NODE DISSECTION FOR CLINICALLY RECURRENT PROSTATE CANCER: RESULTS OF A SINGLE INSTITUTION SERIES WITH A MINIMUM FOLLOW-UP OF 5 YEARS. *Journal of Urology*, **2014**, 191,	2.5	6
78	Preoperative circulating sex hormones are not predictors of positive surgical margins at open radical prostatectomy. *World Journal of Urology*, **2012**, 30, 533-9	4	6
77	Unsuccessful investigation of preoperative sexual health issues in the prostate cancer "couple": results of a real-life psychometric survey at a major tertiary academic center. *Journal of Sexual Medicine*, **2009**, 6, 3347-55	1.1	6
76	Biopsies performed at tertiary care centers are superior to referral biopsies in predicting pathologic Gleason sum. *Journal of Endourology*, **2008**, 22, 533-8	2.7	6
75	Development of a Prediction Tool for Exclusive Locoregional Recurrence After Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer. *Clinical Genitourinary Cancer*, **2019**, 17, 7-14.e3	3.3	6
74	Long-term incidence of secondary bladder and rectal cancer in patients treated with brachytherapy for localized prostate cancer: a large-scale population-based analysis. *BJU International*, **2019**, 124, 1006-1013	5.6	5
73	Circulating sex steroids and prostate cancer: introducing the time-dependency theory. *World Journal of Urology*, **2013**, 31, 267-73	4	5
72	Potency after Radical Prostatectomy: From New Techniques to Better Results. *EAU-EBU Update Series*, **2006**, 4, 33-45		5
71	695: There is no Significant difference between on-Demand PDE5-I Vs PDE5-I As Rehabilitative Treatment in Patients Treated by Bilateral Nerve-Sparing Radical Retropubic Prostatectomy. *Journal of Urology*, **2006**, 175, 225-225	2.5	5
70	Molecular Characterization of Residual Bladder Cancer after Neoadjuvant Pembrolizumab. *European Urology*, **2021**, 80, 149-159	10.2	5
69	Is There a Detrimental Effect of Antibiotic Therapy in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Pembrolizumab?. *European Urology*, **2021**, 80, 319-322	10.2	5
68	Radical Cystectomy in Pathological T4a and T4b Bladder Cancer Patients: Is There Any Space for Sub Stratification?. *Urologia Internationalis*, **2019**, 102, 269-276	1.9	4
67	Contemporary use and survival after perioperative systemic chemotherapy in patients with locally advanced non-metastatic urothelial carcinoma of the bladder treated with radical cystectomy. *European Journal of Surgical Oncology*, **2019**, 45, 1253-1259	3.6	4

66	Contemporary conditional cancer-specific survival after radical nephroureterectomy in patients with nonmetastatic urothelial carcinoma of upper urinary tract. *Journal of Surgical Oncology*, **2020**, 121, 1154-1161	2.8	4
65	Effect of Stage Migration on Bladder Cancer: A Slow but Steady Improvement in Long-Term Survival Rates After Radical Cystectomy in Previous 25 Years. *Clinical Genitourinary Cancer*, **2017**, 15, e223-e228	3.3	4
64	EFFECTIVENESS OF PRE-OPERATIVE PELVIC FLOOR MUSCLE TRAINING FOR POST-PROSTATECTOMY EARLY CONTINENCE RECOVERY. *Journal of Urology*, **2009**, 181, 591	2.5	4
63	Prophylaxis of erectile function after radical prostatectomy with phosphodiesterase type 5 inhibitors. *Current Pharmaceutical Design*, **2009**, 15, 3496-501	3.3	4
62	The Evolution of Staging of Lymph Node Metastases in Clinically Localized Prostate Cancer. *EAU-EBU Update Series*, **2007**, 5, 153-162		4
61	Emerging oral drugs for erectile dysfunction. *Expert Opinion on Emerging Drugs*, **2004**, 9, 179-189	3.7	4
60	Trends and Social Barriers for Inpatient Palliative Care in Patients With Metastatic Bladder Cancer Receiving Critical Care Therapies. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2019**, 17, 1344-1352	7.3	4
59	The impact of treatment modality on survival in patients with clinical node-positive bladder cancer: results from a multicenter collaboration. *World Journal of Urology*, **2021**, 39, 443-451	4	4
58	Predicting local failure after radical cystectomy in patients with bladder cancer: Implications for the selection of candidates at adjuvant radiation therapy. *Urologic Oncology: Seminars and Original Investigations*, **2017**, 35, 672.e1-672.e6	2.8	3
57	Prevention and Management of Postprostatectomy Erectile Dysfunction. *European Urology Supplements*, **2009**, 8, 80-87	0.9	3
56	MORTALITY PREDICTIONS IN PATIENTS WITH ADRENOCORTICAL CARCINOMA. *Journal of Urology*, **2009**, 181, 9-10	2.5	3
55	VALIDATION OF THE CRITERIA SUGGESTED BY CURRENT GUIDELINES TO INDICATE THE NEED FOR BASELINE STAGING BONE SCAN IN PATIENTS WITH NEWLY DIAGNOSED PROSTATE CANCER. *Journal of Urology*, **2009**, 181, 782-782	2.5	3
54	Cell death and cell proliferation in human spina bifida. *Birth Defects Research Part A: Clinical and Molecular Teratology*, **2016**, 106, 104-13		3
53	Evaluation of Cause of Death After Radical Cystectomy for Patients With Bladder Cancer: The Impact of Age at the Time of Surgery. *Clinical Genitourinary Cancer*, **2019**, 17, e541-e548	3.3	3
52	How to improve patient selection for neoadjuvant chemotherapy in bladder cancer patients candidate for radical cystectomy and pelvic lymph node dissection. *World Journal of Urology*, **2020**, 38, 1229-1233	4	3
51	[18F]Fluoro-Deoxy-Glucose positron emission tomography to evaluate lymph node involvement in patients with muscle-invasive bladder cancer receiving neoadjuvant pembrolizumab. *Urologic Oncology: Seminars and Original Investigations*, **2021**, 39, 235.e15-235.e21	2.8	3
50	Intermediate- and high-risk nonmuscle invasive bladder cancer: Where do we stand?. *Urologic Oncology: Seminars and Original Investigations*, **2021**, 39, 631-641	2.8	3
49	Surgery and erectile dysfunction. *Archivos Espanoles De Urologia*, **2010**, 63, 640-8	0.4	3

48	MP58-10 PREOPERATIVE HEMOGLOBIN TO PLATELET RATIO AS A PREDICTOR OF SURVIVAL AFTER RADICAL CYSTECTOMY.. *Journal of Urology*, **2017**, 197,	2.5	2
47	MP51-15 TIME FROM SURGERY TO URINARY CONTINENCE SIGNIFICANTLY INFLUENCES THE SUBSEQUENT RECOVERY OF ERECTILE FUNCTION IN PATIENTS TREATED WITH BILATERAL NERVE-SPARING RADICAL PROSTATECTOMY. *Journal of Urology*, **2014**, 191,	2.5	2
46	ACCEPTANCE OF AND DISCONTINUATION RATE FROM PAROXETINE TREATMENT IN PATIENTS WITH LIFELONG PREMATURE EJACULATION: AN OBSERVATIONAL SURVEY AT A MAJOR TERTIARY ACADEMIC CENTRE. *Journal of Urology*, **2009**, 181, 530-530	2.5	2
45	The case for postoperative PDE-5 inhibitor drug treatment after radical prostatectomy. *Journal of Endourology*, **2008**, 22, 2025-7; discussion 2035	2.7	2
44	639: Prediction of the Probability of Metastatic Disease after Nephrectomy for Renal Cell Carcinoma: European Validation of a Multi-Institutional Nomogram. *Journal of Urology*, **2007**, 177, 214-214	2.5	2
43	Increasing Rates of Perioperative Chemotherapy are Associated With Improved Survival in Men With Urothelial Bladder Cancer With Prostatic Stromal Invasion. *Clinical Genitourinary Cancer*, **2020**, 18, 35-44.e1	3.3	2
42	Prediction of the Need for an Extended Lymphadenectomy at the Time of Radical Cystectomy in Patients with Bladder Cancer. *European Urology Focus*, **2021**, 7, 1067-1074	5.1	2
41	Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration. *BJU International*, **2021**, 128, 607-614	5.6	2
40	Sex- and age-related differences in the distribution of bladder cancer metastases. *Japanese Journal of Clinical Oncology*, **2021**, 51, 976-983	2.8	2
39	Molecular subtyping and immune-gene signatures identify a subset of early bladder tumors as candidates for single-agent immune-checkpoint inhibition. *Urologic Oncology: Seminars and Original Investigations*, **2021**, 39, 734.e11-734.e17	2.8	2
38	The impact of completeness of last transurethral resection of bladder tumors on the outcomes of radical cystectomy. *World Journal of Urology*, **2019**, 37, 2707-2714	4	1
37	Rates of other-cause mortality after radical cystectomy are decreasing over time-A population-based analysis over two decades. *Journal of Surgical Oncology*, **2020**, 121, 1329-1336	2.8	1
36	774 HEAD-TO-HEAD COMPARISON OF LYMPH NODE DENSITY AND NUMBER OF POSITIVE LYMPH NODES IN STRATIFYING THE OUTCOME OF PATIENTS WITH LYMPH NODE POSITIVE PROSTATE CANCER SUBMITTED TO RADICAL PROSTATECTOMY AND EXTENDED PELVIC LYMPH NODE DISSECTION. *Journal of Urology*, **2013**, 189,	2.5	1
35	1838 WHEN TO PERFORM LYMPH NODE DISSECTION IN RENAL CELL CARCINOMA PATIENTS: A NOVEL APPROACH TO PREOPERATIVELY ASSESS THE RISK OF LYMPH NODE INVASION AT SURGERY AND NODAL PROGRESSION DURING FOLLOW UP. *Journal of Urology*, **2013**, 189,	2.5	1
34	Fascial Layers in Nerve Sparing Robot-Assisted Radical Prostatectomy. *Urology Practice*, **2014**, 1, 86-91	0.8	1
33	771 SHOULD AN EXTENDED NODAL TEMPLATE FOR HIGH RISK PROSTATE CANCER ALWAYS INCLUDE REMOVAL OF COMMON ILIAC LYMPH NODES?. *Journal of Urology*, **2012**, 187,	2.5	1
32	Spatial distribution of positive cores improves the selection of patients with low-risk prostate cancer as candidates for active surveillance. *BJU International*, **2013**, 112, E234-42	5.6	1
31	Robot-Assisted Cystectomy: Strengths and Weaknesses. *European Urology Supplements*, **2011**, 10, e12-e169	1	1

30	Editorial comment on: current applications for prostate-specific antigen doubling time. *European Urology*, **2008**, 54, 302	10.2	1
29	Editorial comment on: Outcome of prostate cancer patients with initial PSA> or =20 ng/ml undergoing radical prostatectomy. *European Urology*, **2007**, 52, 1065-6	10.2	1
28	Lower urinary tract symptoms and sexual dysfunction in women. *Current Sexual Health Reports*, **2007**, 4, 85-90	1.2	1
27	Final results of PEANUT: Pembrolizumab and nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as salvage therapy for metastatic urothelial carcinoma (UC).. *Journal of Clinical Oncology*, **2020**, 38, 5017-5017	2.2	1
26	The prognostic significance of capsular incision into tumor during radical prostatectomy. *International Braz J Urol: Official Journal of the Brazilian Society of Urology*, **2011**, 37, 549-550	2	1
25	Re: Siamak Daneshmand, Azadeh Nazemi. Neoadjuvant Chemotherapy in Variant Histology Bladder Cancer: Current Evidence. Eur Urol Focus 2020;6:639-41. *European Urology Focus*, **2021**, 7, 1506-1507	5.1	1
24	Incidence and Clinical Impact of Inflammatory Fluorodeoxyglucose Positron Emission Tomography Uptake After Neoadjuvant Pembrolizumab in Patients with Organ-confined Bladder Cancer Undergoing Radical Cystectomy. *European Urology Focus*, **2021**, 7, 1092-1099	5.1	1
23	Adjuvant chemotherapy is ineffective in patients with bladder cancer and variant histology treated with radical cystectomy with curative intent. *World Journal of Urology*, **2021**, 39, 1947-1953	4	1
22	Incidental Prostate Cancer (cT1a-cT1b) Is a Relevant Clinical and Research Entity and Should Be Fully Discussed in the International Prostate Cancer Guidelines. *European Urology Oncology*, **2021**,	6.7	1
21	Concomitant antibiotics (ATBs) use and survival outcomes in patients (pts) with muscle-invasive bladder cancer (MIBC) treated with neoadjuvant pembrolizumab (PURE-01 study).. *Journal of Clinical Oncology*, **2021**, 39, 449-449	2.2	1
20	PECULIAR: An open label, multicenter, single-arm, phase 2 study of neoadjuvant pembrolizumab (PEM) and epacadostat (EPA), preceding radical cystectomy (Cy), for patients (pts) with muscle-invasive urothelial bladder cancer (MIUBC).. *Journal of Clinical Oncology*, **2018**, 36, TPS4595-TPS4595	2.2	0
19	Editorial comment on: tumour grade, treatment, and relative survival in a population-based cohort of men with potentially curable prostate cancer. *European Urology*, **2010**, 57, 639	10.2	
18	Editorial comment on: the periprostatic autonomic nerves--bundle or layer?. *European Urology*, **2008**, 54, 1117	10.2	
17	Sutent Relieves Renal Cell Carcinoma Spinal Cord Compression: Part II. *European Urology*, **2007**, 52, 273-274	10.2	
16	Reply to Carsten Stephan et al Letter to the Editor re: Felix K.-H. Chun, Markus Graefen, Alberto Briganti, Andrea Gallina, Julia Hopp, Michael W. Kattan, Hartwig Huland and Pierre I. Karakiewicz. Initial Biopsy Outcome Prediction Head-to-Head Comparison of a Logistic Regression-Based Nomogram versus Artificial Neural Network. Eur Urol 2007;51:1236 3. *European Urology*, **2007**, 51, 1448	10.2	
15	Clinical Case Debate: Neoadjuvant Checkpoint Inhibition Versus Standard Chemotherapy **2022**, 13-25		
14	Association of an immune gene signature with pathologic response and outcome after neoadjuvant pembrolizumab (pembro), compared to neoadjuvant chemotherapy (NAC), in muscle-invasive bladder cancer (MIBC).. *Journal of Clinical Oncology*, **2020**, 38, 533-533	2.2	
13	Development of a composite biomarker-based calculator to predict the probability of pathologic complete response (pT0) after neoadjuvant pembrolizumab (pembro) in muscle invasive bladder cancer (MIBC).. *Journal of Clinical Oncology*, **2020**, 38, 539-539	2.2	

12	Re: Ten-Year Oncologic Outcomes following Robot-Assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium. *Journal of Urology*, **2020**, 203, 624	2.5
11	First survival outcomes and additional secondary analyses from PURE-01: Pembrolizumab (pembro) before radical cystectomy (RC) in muscle-invasive urothelial bladder carcinoma (MIBC).. *Journal of Clinical Oncology*, **2019**, 37, 391-391	2.2
10	Squamous-cell carcinoma variant histology (SCC-VH) in muscle-invasive bladder cancer (MIBC): A comprehensive clinical, genomic, and therapeutic assessment from multiple datasets.. *Journal of Clinical Oncology*, **2019**, 37, 4535-4535	2.2
9	Towards the noninvasive identification of pathologic responders to neoadjuvant pembrolizumab in muscle-invasive urothelial bladder cancer (MIBC).. *Journal of Clinical Oncology*, **2019**, 37, 4540-4540	2.2
8	Dissecting outcomes of patients (pts) with . *Journal of Clinical Oncology*, **2020**, 38, 5043-5043	2.2
7	Racial differences in the distribution of bladder cancer metastases: a population-based analysis. *Central European Journal of Urology*, **2020**, 73, 407-415	0.9
6	The Utility of PDE5 Inhibitors After Radical Prostatectomy **2009**, 177-196	
5	Penile Rehabilitation After Robotic Radical Prostatectomy: The Best Strategy **2011**, 361-370	
4	Mid-term complications after placement of the male adjustable suburethral sling: a single center experience. *International Braz J Urol: Official Journal of the Brazilian Society of Urology*, **2011**, 37, 552-553	2
3	Re: Paolo Dell'Oglio, Elio Mazzone, Edward Lambert, et al. The Effect of Surgical Experience on Perioperative and Oncological Outcomes After Robot-assisted Radical Cystectomy with Intracorporeal Urinary Diversion: Evidence from a Referral Centre with Extensive Experience in	5.1
2	Re: Hugh Mostafid, Ashish M. Kamat, Siamak Daneshmand, et al. Best Practices to Optimise Quality and Outcomes of Transurethral Resection of Bladder Tumours. Eur Urol Oncol 2021;4:12-9. *European Urology Oncology*, **2021**, 4, 126	6.7
1	Dissecting patterns of care in patients with variant histology of bladder cancer and lymph node invasion. *Società Internationale Urologie Journal*, **2021**, 282-298	0.1